Residency · Residency · Geriatrics

Sensory Impairment - Vision and Hearing Loss

Introduction

Sensory impairment ranks among the most prevalent and profoundly impactful conditions affecting elderly populations, yet its significance is frequently underestimated in clinical practice. Vision impairment affects approximately 13 percent of adults aged 65 and older and 25 percent of those aged 80 and above, with the leading causes being age-related macular degeneration, cataracts, glaucoma, and diabetic retinopathy. Hearing loss is even more prevalent, affecting 33 percent of adults aged 65 to 74, 50 percent of those aged 75 and above, and up to 80 percent of those aged 85 and older. Dual sensory impairment, the combination of vision and hearing loss, affects 10 to 20 percent of the elderly population and is profoundly disabling.

The clinical impact of sensory impairment extends far beyond the immediately apparent difficulties with seeing and hearing. Sensory impairment is independently associated with cognitive decline, dementia, depression, social isolation, falls, functional decline, reduced quality of life, and increased mortality. Both vision and hearing loss are undertreated, with 75 percent of hearing loss being correctable yet only 20 to 30 percent of affected elderly using hearing aids. This treatment gap represents a substantial and preventable burden of disability, and the geriatrician's awareness and proactive management of sensory impairment is essential for comprehensive care.

Vision Impairment

Age-Related Macular Degeneration (AMD)

Age-related macular degeneration is the leading cause of irreversible vision loss in adults aged 65 and older in developed countries, with a prevalence of approximately 10 percent in those aged 65 to 74 and 25 percent in those aged 75 and above. AMD exists in two forms with markedly different clinical trajectories. Dry AMD, accounting for 85 to 90 percent of cases, involves the gradual accumulation of drusen (lipid-protein deposits beneath the retinal pigment epithelium) and may progress to geographic atrophy, producing slow, progressive central vision loss over years. Wet or neovascular AMD, accounting for 10 to 15 percent of cases, involves the development of abnormal choroidal blood vessels that leak fluid and blood beneath the retina, causing rapid central vision loss that constitutes an ophthalmologic urgency.

Risk factors for AMD include advancing age, smoking (which increases risk 2- to 3-fold), family history, white race, cardiovascular disease, and ultraviolet light exposure. Patients experience central scotoma, metamorphopsia (distortion of straight lines), and difficulty recognizing faces and reading. Home monitoring with the Amsler grid allows patients to detect new metamorphopsia that may signal conversion from dry to wet AMD, and fundoscopic examination revealing drusen confirms the diagnosis.

Treatment for dry AMD centers on the AREDS2 supplementation regimen, consisting of vitamin C 500 mg, vitamin E 400 IU, zinc 80 mg, copper 2 mg, lutein 10 mg, and zeaxanthin 2 mg, which reduces progression to advanced AMD by approximately 25 percent. Beta-carotene must not be included because of its association with increased lung cancer risk in current and former smokers. Recent advances have brought the first treatments capable of slowing geographic atrophy progression: pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay), both complement inhibitors administered as intravitreal injections, represent a breakthrough for a condition previously considered untreatable.

Wet AMD treatment has been revolutionized by anti-VEGF intravitreal injections. Ranibizumab (Lucentis), aflibercept (Eylea), bevacizumab (Avastin, used off-label at significantly lower cost with equivalent efficacy), and faricimab (Vabysmo, a bispecific antibody allowing longer treatment intervals) are the available agents. Treatment typically begins with monthly injections, transitioning to treat-and-extend protocols that extend the interval between injections as stability is achieved. Anti-VEGF therapy improves or stabilizes vision in approximately 90 percent of treated patients. The critical clinical message is that wet AMD requires treatment within days to weeks of symptom onset to preserve vision, and delayed treatment leads to irreversible central vision loss.

Cataracts

Cataracts are the most common cause of reversible vision loss worldwide, with a prevalence of 50 percent by age 75 and 70 percent by age 80. The most common type, nuclear sclerotic cataract, produces gradual visual deterioration. Cortical cataracts affect the lens periphery, and posterior subcapsular cataracts, which progress most rapidly and are associated with corticosteroid use, produce early visual symptoms. Patients experience gradual blurred vision, glare sensitivity, difficulty with night driving, faded color perception, and frequent changes in corrective lens prescriptions.

Cataract surgery using phacoemulsification with intraocular lens implantation is the most commonly performed surgery worldwide, achieving improvement in visual acuity in 95 percent of cases. Beyond visual improvement, cataract surgery reduces fall risk by 34 percent, as demonstrated by Harwood and colleagues, making it one of the most effective single interventions for fall prevention in the elderly. The procedure is safe even in very elderly patients and those with mild-to-moderate dementia. Complications, including posterior capsular opacification (20 to 30 percent, treatable with YAG laser capsulotomy), endophthalmitis (less than 0.1 percent), and retinal detachment (less than 1 percent), are infrequent and generally manageable.

Glaucoma

Glaucoma is the second leading cause of irreversible blindness worldwide, often termed the "silent thief of sight" because peripheral vision loss progresses insidiously before central vision is affected. Open-angle glaucoma, the most common form accounting for 90 percent of cases, progresses slowly and asymptomatically. Risk factors include advancing age, Black race (which confers a 4-fold increased risk), family history, elevated intraocular pressure, and myopia. Screening requires comprehensive eye examination including tonometry and optic disc evaluation.

Treatment aims to lower intraocular pressure to prevent optic nerve damage. Topical medications include prostaglandin analogs (latanoprost, the first-line agent), beta-blockers (timolol, which must be avoided in patients with asthma, COPD, or bradycardia), alpha-agonists (brimonidine), and carbonic anhydrase inhibitors. Selective laser trabeculoplasty is now considered a first-line alternative to topical drops based on the LiGHT trial, which demonstrated equivalent efficacy with improved adherence. Surgical options include trabeculectomy and minimally invasive glaucoma surgery (MIGS) procedures.

Diabetic Retinopathy

Diabetic retinopathy is the most common cause of blindness in working-age adults and is increasing in prevalence among elderly individuals with long-standing diabetes. The disease progresses through stages of non-proliferative retinopathy (mild, moderate, and severe) to proliferative retinopathy characterized by neovascularization. Diabetic macular edema is the leading cause of vision loss in diabetic retinopathy. Annual dilated eye examination is recommended for all diabetic patients. Treatment includes optimized glycemic and blood pressure control, anti-VEGF injections for diabetic macular edema, and panretinal photocoagulation for proliferative disease.

Impact on Geriatric Syndromes

Vision impairment has pervasive effects on geriatric health outcomes. Fall risk increases 1.5- to 2-fold with visual impairment, and multifocal or progressive lenses paradoxically increase outdoor fall risk by impairing depth perception on uneven surfaces. Sensory deprivation is a recognized risk factor for delirium, and ensuring that patients have access to corrective lenses during hospitalization is an important delirium prevention measure. The ARIC study demonstrated that vision impairment is independently associated with faster cognitive decline. Depression affects 20 to 30 percent of visually impaired elderly. Visual acuity and visual field integrity directly impact driving safety, making vision assessment a key component of driving fitness evaluation.

<image>A clinical visual impairment reference guide for geriatricians. Show four panels representing the major causes of vision loss in elderly, each depicting what the patient sees through their affected eye. Panel 1 — AMD: show a scene (e.g., a face or clock) with a central dark/blurred scotoma, demonstrating loss of central vision with preserved peripheral vision; include an Amsler grid showing wavy/distorted lines. Panel 2 — Cataracts: show the same scene appearing hazy, washed out, and glare-affected, as if looking through a dirty window. Panel 3 — Glaucoma: show the same scene with preserved central vision but constricted peripheral visual field (tunnel vision effect). Panel 4 — Diabetic Retinopathy: show the scene with scattered dark spots (vitreous hemorrhage) and areas of blurriness (macular edema). Below each panel, include: prevalence in elderly, primary symptoms, screening method, urgency of treatment, and first-line treatment. Highlight that cataracts are REVERSIBLE while AMD, glaucoma, and diabetic retinopathy cause IRREVERSIBLE damage if untreated.</image>

Hearing Loss

Types

Presbycusis, or age-related sensorineural hearing loss, is the most common cause of hearing loss in the elderly. It is bilateral, symmetric, progressive, and characteristically affects high frequencies first, reflecting the loss of outer and inner hair cells in the cochlea, atrophy of the stria vascularis, and neural degeneration. Conductive hearing loss, caused by mechanical impediments to sound transmission, has several important causes in the elderly. Cerumen impaction is the single most common correctable cause of hearing loss, affecting 30 to 40 percent of elderly individuals and remediable with simple removal. Otosclerosis, middle ear effusion, and tympanic membrane perforation are additional conductive causes. Mixed hearing loss combines sensorineural and conductive components. Central auditory processing disorder, in which patients have difficulty understanding speech despite adequate peripheral hearing, is associated with cognitive decline and represents a distinct challenge for rehabilitation.

Clinical Impact

The clinical consequences of hearing loss in the elderly are far more profound than the mere inability to hear conversational speech. Communication difficulties lead to social isolation, which fosters depression, which accelerates cognitive decline, creating a destructive cycle of progressive disability. The 2020 Lancet Commission on Dementia identified hearing loss as the single largest modifiable risk factor for dementia, accounting for 9 percent of population-attributable risk, a contribution greater than that of hypertension, obesity, or physical inactivity.

The ACHIEVE trial, published in 2023, provided landmark evidence by demonstrating that a hearing intervention consisting of hearing aids and audiologic counseling reduced cognitive decline by 48 percent over 3 years in at-risk elderly individuals with elevated cardiovascular risk but intact baseline cognition. This was the first randomized controlled trial to establish that treating hearing loss can slow cognitive decline, transforming hearing loss management from a quality-of-life intervention to a cognitive preservation strategy. Additional consequences of untreated hearing loss include increased fall risk (1.4-fold increase per 10 dB of hearing loss), depression (1.5- to 2-fold increased risk), and during hospitalization, increased length of stay and delirium risk.

Screening and Diagnosis

Several screening approaches are available for identifying hearing loss in clinical practice. The whispered voice test, performed by whispering a two-syllable word at arm's length from each ear, is simple but has low sensitivity. The finger rub test can detect moderate-to-severe loss. The Hearing Handicap Inventory for the Elderly-Screening (HHIE-S), a 10-item questionnaire with a score of 10 or above suggesting hearing handicap, provides a structured self-assessment. Audiometry remains the gold standard, with pure-tone audiometry measuring thresholds across various frequencies. Normal hearing is defined as thresholds of 25 dB HL or below, with mild loss at 26 to 40 dB, moderate at 41 to 55 dB, moderate-severe at 56 to 70 dB, severe at 71 to 90 dB, and profound above 90 dB. Speech discrimination testing, which assesses the ability to understand spoken words, is particularly important for determining hearing aid candidacy.

The USPSTF concluded in 2021 that there is insufficient evidence to recommend screening in asymptomatic adults aged 50 and older, though most geriatric organizations recommend routine screening given the high prevalence and treatable nature of the condition. Otoscopy should always be performed to assess for cerumen impaction, which affects 30 to 40 percent of elderly individuals and represents an easily treatable cause of hearing loss.

Management

Hearing Aids

Hearing aids are recommended for mild-to-moderate sensorineural hearing loss and are available in multiple configurations including behind-the-ear, in-the-ear, in-the-canal, and completely-in-canal designs. The FDA approval of over-the-counter hearing aids in 2022 was a landmark regulatory change that increased access and reduced cost for individuals with mild-to-moderate hearing loss. OTC devices are not suitable for severe hearing loss or for patients who require professional fitting and programming. Traditional prescription hearing aids, fitted and programmed by audiologists, offer greater customization and are appropriate for the full range of hearing loss severity.

Significant challenges limit hearing aid utilization in elderly patients. Dexterity issues may impede handling of small devices and battery changes. Cognitive impairment may complicate the learning process for new technology. Cost remains a major barrier, with prescription hearing aids averaging $2,000 to $7,000 per pair, and Medicare does not cover hearing aids. Stigma around wearing hearing devices persists. Compliance is poor, with only 20 to 30 percent of individuals who would benefit from hearing aids actually using them. Satisfaction and adherence improve substantially with proper fitting, audiologic counseling, and regular follow-up.

Cochlear Implants

Cochlear implants are appropriate for patients with severe-to-profound sensorineural hearing loss who derive insufficient benefit from hearing aids, typically defined by a speech recognition score below 50 percent in the best-aided ear. Cochlear implantation is safe and effective in elderly patients, with no upper age limit. Outcomes include significant improvements in speech perception, quality of life, depression, and cognitive function. Medicare Part B covers cochlear implants, providing an important access pathway for eligible elderly patients.

Assistive Listening Devices

Assistive listening devices complement hearing aids and provide targeted amplification for specific situations. Amplified telephones, TV amplifiers, and personal amplifiers (such as the pocket talker) provide immediate benefit. Hearing loop systems work with telecoil-equipped hearing aids. Smartphone applications offer sound amplification and real-time captioning. Visual alerts, including flashing doorbells and vibrating alarm clocks, address safety concerns for patients with significant hearing loss.

Communication Strategies

Effective communication strategies are essential for all clinical encounters with hearing-impaired elderly patients. Clinicians should face the patient directly to provide lip-reading cues, reduce background noise, speak clearly at a normal pace without exaggerated slowness, and rephrase rather than simply repeat when not understood. Shouting should be avoided because it distorts sound quality. Most importantly, clinicians should ensure that hearing aids are in place, turned on, and functioning during all clinical encounters, a simple measure that is frequently overlooked.

<image>A hearing loss management pathway for elderly patients. Start with "Suspected hearing loss (communication difficulty, social withdrawal, asking to repeat, TV too loud)." First step: "Otoscopy — check for cerumen impaction" — if present: "Remove cerumen (irrigation or curettage) — reassess." If clear: "Audiometry referral." Show audiometry results branching: Mild-Moderate (26-55 dB) → "Hearing aid trial (OTC for mild; prescription for moderate); communication strategies; assistive devices." Moderate-Severe (56-70 dB) → "Prescription hearing aid fitting with audiologist; consider cochlear implant evaluation if poor speech discrimination." Severe-Profound (>70 dB) → "Cochlear implant evaluation; specialist referral." Include a sidebar showing the ACHIEVE trial results: hearing intervention reduced cognitive decline by 48% in at-risk elderly — reinforcing that treating hearing loss is a cognitive preservation strategy. Include a box about OTC hearing aids: who they are appropriate for, advantages (lower cost, easier access), and limitations (no professional fitting, not for severe loss). Show the Lancet Commission statistic: hearing loss is the #1 modifiable risk factor for dementia (9% population attributable fraction).</image>

Dual Sensory Impairment

Combined vision and hearing loss affects 10 to 20 percent of elderly individuals aged 80 and older and produces a level of disability that exceeds the sum of its individual components. Dual sensory impairment profoundly impacts communication, mobility, social participation, and safety. It carries the strongest association with depression, cognitive decline, and institutionalization of any single geriatric syndrome. Management requires coordinated ophthalmological and audiological care, maximization of residual function in both sensory modalities, occupational therapy for adaptive strategies, and social services for ongoing support. The combination of sensory deficits demands particular attention to environmental modification, communication technique, and caregiver education.

Key Clinical Pearls

• Hearing loss is the single LARGEST modifiable risk factor for dementia (Lancet Commission 2020) — the ACHIEVE trial showed hearing aids reduced cognitive decline by 48% in at-risk elderly; treat hearing loss as a cognitive preservation strategy
• Cerumen impaction is the most common correctable cause of hearing loss in elderly — always check with otoscopy before assuming sensorineural loss; 30-40% of elderly have impacted cerumen
• Cataract surgery is the most effective single intervention for vision-related fall prevention — it reduces falls by 34% and should not be withheld based on age alone
• OTC hearing aids (FDA approved 2022) have expanded access for mild-moderate hearing loss at lower cost — geriatricians should educate patients about this option
• Sensory impairment is a delirium risk factor — ensure hearing aids and glasses are present and functioning during all hospitalizations and clinical encounters
• Wet AMD requires URGENT anti-VEGF treatment (days to weeks) to preserve vision — delayed treatment leads to irreversible central vision loss
• Multifocal/progressive eyeglasses increase outdoor fall risk — recommend single-distance lenses for walking and stairs

References

1. Lin FR, Pike JR, Albert MS, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. Lancet. 2023;402(10404):786-797.
2. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446.
3. Harwood RH, Foss AJ, Osborn F, et al. Falls and health status in elderly women following first eye cataract surgery: a randomised controlled trial. Br J Ophthalmol. 2005;89(1):53-59.
4. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221-e1234.
5. Reed NS, Altan A, Deal JA, et al. Trends in health care costs and utilization associated with untreated hearing loss over 10 years. JAMA Otolaryngol Head Neck Surg. 2019;145(1):27-34.

Read this lecture as Markdown